The membrane receptor ErbB2 (also known as HER2/neu) is a member of the epidermal growth factor receptor (EGFR) family. ErbB2 is amplified and overexpressed in many epithelial-derived malignancies including breast, ovarian, and lung cancers. Agents capable of selectively targeting ErbB2 can be used for diagnostics, prognostic indications, imaging and therapeutic applications.
Novel anti-ErbB2 peptides
The inventors have used an in silico approach to identify peptides that bind selectively to ErbB2. These peptides can be used for early non-invasive detection of ErbB2 positive cancer and provide a means to monitor disease progression without the need for a biopsy. Anti-ErbB2 peptides can also be developed to mediate drug delivery specifically to the ErbB2 expressing cancer cells.
- Early detection of ErbB2 in many types of solid tumors
- Non-invasive diagnostic approach to identify and monitor ErbB2 positive cancer
- Therapeutic coupling of peptide with a drug for targeted delivery
- Peptides have rapid binding kinetics, low toxicity, high target affinity, and are inexpensive to synthesize
- Peptides can achieve deep tissue penetration with minimal immunogenicity compared to antibodies